Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2849 - Diagnostic value of methylation status of T-UCRs for colorectal cancer


08 Oct 2016


Poster Display


Anastasia Kottorou


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


A. Kottorou1, A. Antonacopoulou1, F. Dimitrakopoulos1, G. Diamantopoulou2, T. Theodorakopoulos2, C. Oikonomou3, I. Koukourikou3, D. Dalla2, P. Karatasou2, E. Katsakoulis2, A. Koutras1, T. Makatsoris1, M. Stavropoulos4, K. Thomopoulos5, H. Kalofonos1

Author affiliations

  • 1 Clinical And Molecular Oncology Laboratory, Medical School, University of Patras, 26504 - Patras/GR
  • 2 Division Of Gastroenterology, University Hospital Patras, 26504 - Patras/GR
  • 3 Division Of Oncology, University Hospital Patras, 26504 - Patras/GR
  • 4 Department Of Surgery, University of Patras, 26504 - Patras/GR
  • 5 Division Of Gastroenterology, Medical School, University of Patras, 26504 - Patras/GR


Abstract 2849


Expression of Transcribed Ultra Conserved Regions (T-UCRs) is often dysregulated in various types of cancer. Regulation of T-UCR expression includes epigenetic mechanisms, and in particular CpG island methylation. Three T-UCRs (160, 283 and 346) have been found to be methylated in colon adenocarcinomas. The present study assesses the use of the T-UCR methylation status in circulating DNA as a diagnostic marker for colorectal cancer (CRC).


Expression and methylation levels of T-UCRs 160, 283 and 346 were assessed in neoplastic and paired normal colonic fresh frozen tissue specimens from 75 CRC patients, as well as in 5 fresh frozen adenoma tissue specimens. Methylation status of the three T-UCRs was also determined in plasma from 161 patients (56 CRC patients, 55 adenoma patients, 40 healthy subjects and 10 patients with colon inflammation or diverticulosis).


Expression levels of all three T-UCRs were lower in neoplastic tissues, compared to normal adjacent colonic tissues, but only in T-UCR 160 the difference was statistically significant (p 


Methylation of T-UCR 160 in plasma has great specificity for CRC but low sensitivity. Alteration of the methodological approaches to improve the sensitivity could result in a promising non-invasive screening method for CRC.

Clinical trial identification

Legal entity responsible for the study

University of Patras


University of Patras


T. Makatsoris: Travel Pfizer, Roche, Astellas. Advisory: Roche, Boehringer. Honoraria: Roche, Sanofi, Merck, Amgen. H. Kalofonos: Travel: Pfizer, Roche, Novartis, Enorasis Advisory: Roche, Novartis, MSD, Genesis, Pfizer, Lilly, Leo, Amgen, Janssen, Merck, Merck Serono. Research Funding: Roche, Novartis, MSD, Genesis, Pfizer, Lilly, Bayer, Amgen, Janssen, Merck Serono. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings